Discovery Toxicology studies (in-vitro)

Compound liability of undesirable effects has become a major issue that could hinder or halt the development of candidate drugs or even withdrawal from the market. In vitro discovery toxicology studies are used to determine undesirable off-target activity during early stages. BioMedha offers the following key discovery toxicology studies (indicative and non-GLP format):

  • Cytotoxicity assays to predict target-organ toxicity
  • Mitochondrial toxicity (membrane potential, electron transport chain, Oxygen consumption, acidification, ATP synthesis)
  • Liver toxicity assays (HepG2 cytotoxicity, apoptosis,  steatosis,  phospholipidosis, lipid peroxidation,  CYP3A4, Pgp and UGT activity)
  • hERG risk: hERG fluorescence polarization-based assay
  • Oxidative stress
  • Lysosomal perturbation
  • DNA damage